Insmed Inc (INSM)

[rfoable1]

io,
That's an easy one - of course it's good news. Iplex (formerly called Somatokine when this study was started) reduced insulin consumption and GH levels in Type 1 diabetics in just 1 week of treatment, which corresponds to increased insulin sensitivity. And this was at 0.4 mg/kg/day.

The FDA-approved range for Iplex in treating IGFD is 0.5 mg/kg/day to 2.0 mg/kg/day. So these positive effects in Type 1 diabetics were obtained with a remarkably low dose.

A solid piece of evidence that Iplex has potential to treat Type 1 diabetics with severe insulin resistance (SIR).
cheers